NCT05996835

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

CompletedPHASE2INTERVENTIONAL

Trial Details

Start: 2024-01-18Est. Completion: 2026-02-25

Enrollment target: 316 participants

Locations

University Of Alabama, Birmingham, Alabama, United States
UC San Francisco Medical Center, San Francisco, California, United States
Stanford Healthcare, Stanford, California, United States
Emory Johns Creek Hospital, Johns Creek, Georgia, United States
Northwestern Memorial Hospital, Evanston, Illinois, United States
Univ Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Med Center, Boston, Massachusetts, United States
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
Baystate Medical Center, Springfield, Massachusetts, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Montefiore Medical Center, The Bronx, New York, United States
Montefiore Medical Center, The Bronx, New York, United States
Wake Forest Univ School of Medicine, Winston-Salem, North Carolina, United States
Ohio State University Medical Center, Columbus, Ohio, United States

Trauma; Complications

Acute Kidney Injury (AKI) occurs in 24% of trauma patients, and is even more common in those with severe trauma. It is a…

Clermont-Ferrand, FranceEst. completion Sep 2027

SepsisAcute Kidney Injury Due to SepsisGastrointestinal MicrobiomeSepsis-Associated Liver InjuryIntensive Care Medicine

Sepsis is a major cause of morbidity and mortality in intensive care units. Sepsis-associated liver injury (SALI) and se…

Hangzhou, ChinaEst. completion Feb 14, 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.